UK neuroscience SME specialising in digital biomarkers and patient stratification for psychiatric and neurodegenerative drug development.
SBGNEURO is a UK-based specialist neuroscience SME focused on translational psychiatry — bridging the gap between academic brain research and pharmaceutical drug development. Their work centres on developing and validating quantitative and digital biomarkers for psychiatric conditions including schizophrenia, major depression, and Alzheimer's disease, with the goal of better stratifying patient populations in clinical trials. They bring a transdiagnostic perspective, treating psychiatric disorders through shared biological mechanisms rather than traditional diagnostic categories. Both their projects were funded under the Innovative Medicines Initiative (IMI2), confirming their role as a specialist scientific partner within pharma-academic R&D consortia.
Both PRISM and PRISM 2 focus on intermediate stratified markers for psychiatric conditions, with PRISM 2 explicitly listing digital biomarkers and quantitative biology as core keywords.
PRISM 2 names translational neuroscience directly; the PRISM programme as a whole is designed to translate research findings into clinically usable stratification tools.
PRISM 2 lists schizophrenia, major depression, and Alzheimer disease alongside 'transdiagnostic' as a keyword, indicating cross-disorder biological analysis rather than siloed disease focus.
The PRISM project title — Psychiatric Ratings using Intermediate Stratified Markers — directly signals expertise in classifying patient subgroups for pharmaceutical development purposes.
SBGNEURO's two projects both belong to the PRISM programme, so their core mission has remained stable: psychiatric patient stratification. However, the transition from PRISM (2016–2019) to PRISM 2 (2021–2024) shows a meaningful deepening: the first project carried no specific keyword tags, while the sequel explicitly names digital biomarkers, quantitative biology, and a transdiagnostic framework — suggesting the organisation moved from foundational marker research toward data-driven, cross-disorder biological profiling. The expansion of disease scope to include Alzheimer's disease alongside classical psychiatric conditions in PRISM 2 indicates a broadening into neurodegenerative territory.
SBGNEURO is moving toward data-driven, cross-diagnostic neuroscience — a direction strongly aligned with pharma interest in precision psychiatry and digital health endpoints for regulatory submissions.
SBGNEURO has never led an H2020 project, always joining as a participant — consistent with a specialist scientific contributor rather than a consortium organiser. Both projects were IMI2-funded, meaning they operate within large pharma-academic consortia (IMI2 consortia routinely include 15–30+ partners), which is reflected in their 29 unique partners across 9 countries. This profile suggests they are a focused expert brought in for specific technical contributions, not a coordinating hub.
SBGNEURO has worked with 29 unique consortium partners across 9 countries, a broad European network concentrated in the IMI2 pharma-academic ecosystem. Their reach is European, likely including major pharmaceutical companies, university hospitals, and academic research centres typical of IMI2 consortia.
SBGNEURO is a rare example of a small private company embedded in IMI2-funded psychiatric research — a space typically dominated by universities and pharmaceutical giants. Their value lies in bringing agile, focused scientific expertise in quantitative biomarker methodology to large consortia that need specialist contributors without the overhead of academic institutions. For consortium builders in precision psychiatry or CNS drug development, they offer a commercially structured partner with deep translational research experience.
